Summary of patient demographics and baseline disease characteristics.
| Variables | Tofacitinib 5 mg BID, n = 107 | Tofacitinib 10 mg BID, n = 104 | ADA 40 mg SC Q2W, n = 106 |
|---|---|---|---|
| Age, yrs, mean (SD) | 49.4 (12.6) | 46.9 (12.4) | 47.4 (11.3) |
| Female, n (%) | 57 (53.3) | 62 (59.6) | 50 (47.2) |
| White, n (%) | 105 (98.1) | 97 (93.3) | 103 (97.2) |
| BMI, kg/m2, mean (SD) | 29.0 (5.2) | 29.3 (5.5) | 28.8 (5.3) |
| Duration of PsA, yrs, mean (SD) | 7.3 (8.2) | 5.4 (5.8) | 5.3 (5.3) |
| DAPSA, mean (SD) | 45.6 (20.3) | 43.7 (19.5) | 38.5 (18.2) |
| Swollen joint count, 66 joints assessed, mean (SD) | 12.9 (9.9) | 11.7 (7.7) | 9.8 (7.9) |
| Tender/painful joint count, 68 joints assessed, mean (SD) | 20.5 (12.6) | 20.3 (12.9) | 17.1 (11.2) |
| HAQ-DI score, mean (SD) | 1.2 (0.6) | 1.1 (0.6) | 1.1 (0.6) |
| Presence of dactylitis, DSS > 0, n (%) | 61 (57.0) | 60 (57.7) | 58 (54.7) |
| Elevated CRP, n (%)* | 68 (63.6) | 66 (63.5) | 64 (60.4) |
| CRP, mg/l, mean (SD) | 10.5 (18.4) | 8.1 (11.2) | 14.3 (24.7) |
| CRP, % | |||
| ≤ 2.87 mg/l | 36.4 | 36.5 | 39.6 |
| > 2.87 to ≤ 10 mg/l | 38.3 | 38.5 | 26.4 |
| > 10 mg/l | 25.2 | 25.0 | 34.0 |
| mTSS > 0, n (%) | 96 (89.7) | 96 (92.3) | 99 (93.4) |
| mTSS, mean (SD)# | 17.1 (28.6) | 10.4 (18.4) | 14.4 (39.2) |
| Erosion > 0, n (%) | 96 (89.7) | 96 (92.3) | 99 (93.4) |
| Erosion, mean (SD)# | 10.8 (16.3) | 6.9 (10.5) | 9.2 (23.2) |
| JSN > 0, n (%) | 51 (47.7) | 39 (37.5) | 38 (35.8) |
| JSN, mean (SD)# | 11.8 (17.0) | 8.6 (11.5) | 13.7 (24.3) |
↵* Defined as > 2.87 mg/l (upper limit of normal).
↵# Among patients with baseline score > 0. ADA: adalimumab; BID: twice daily; BMI: body mass index; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; DSS: dactylitis severity score; HAQ-DI: Health Assessment Questionnaire–Disability Index; JSN: joint space narrowing; mTSS: modified Total Sharp Score; PsA: psoriatic arthritis; Q2W: once every 2 weeks; SC: subcutaneous.